News

PepGen Announces First Participant Dosed in a Phase 1 Clinical Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

Initiation of Phase 1 Study Marks PepGen’s Transition to a Clinical Stage Company    This Phase 1 Healthy Normal Volunteer (HNV) Study will Evaluate Safety and Tolerability as the Primary Objective, and will Begin to Evaluate the Delivery and Target Engagement of PGN-EDO51 to Enable Subsequent Patient Trials BOSTON, April 6, 2022 – PepGen, Inc., …

PepGen Announces First Participant Dosed in a Phase 1 Clinical Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy Read More »

PepGen Appoints Michelle Mellion, M.D., as Senior Vice President, Head of Clinical Development

Dr. Mellion brings deep experience in neuromuscular disease research and treatment as a biopharma executive, researcher and physician BOSTON, April 5, 2022 – PepGen, Inc., a company developing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases, today announced that it has appointed Michelle Mellion, …

PepGen Appoints Michelle Mellion, M.D., as Senior Vice President, Head of Clinical Development Read More »

PepGen Continues to Build Leadership Team with Additions of Senior Vice President, Clinical Operations and Vice President, Toxicology

BOSTON, March 30, 2022 – PepGen, Inc., advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurologic diseases, today announced that it has appointed Jennifer Cormier as Senior Vice President, Clinical Operations and Dr. Jeffrey Foy as Vice President, Toxicology. Ms. Cormier brings over 15 years …

PepGen Continues to Build Leadership Team with Additions of Senior Vice President, Clinical Operations and Vice President, Toxicology Read More »

PepGen Announces Approval by Health Canada of CTA to Begin First in Human Trials of PGN-EDO51 to Treat Duchenne Muscular Dystrophy

Updates on preclinical data and the clinical development plan will be presented at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference BOSTON, March 15, 2022 – PepGen Inc., a company advancing the next generation of oligonucleotide therapies for neuromuscular and neurologic diseases, today announced approval by Health Canada of PepGen’s Clinical Trial Application (CTA) authorizing initiation …

PepGen Announces Approval by Health Canada of CTA to Begin First in Human Trials of PGN-EDO51 to Treat Duchenne Muscular Dystrophy Read More »

PepGen Appoints Laurie Keating as Chair of Board of Directors

Keating brings strong experience as a life science executive and Board member BOSTON, January 19, 2022 – PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, today announced that it has appointed Laurie Keating as Chair of the company’s Board of Directors. “We are very pleased that Laurie has agreed to join …

PepGen Appoints Laurie Keating as Chair of Board of Directors Read More »

PepGen Appoints Vice President of Program Management and Promotes Sonia Bracegirdle, Ph.D., to Senior Vice President, Strategy & Operations

PepGen Appoints Vice President of Program Management and Promotes Sonia Bracegirdle, Ph.D., to Senior Vice President, Strategy & Operations Dr. Bracegirdle to lead expanded PepGen Strategy and Operations team Isami J. Salcedo, experienced biotechnology operations and program management professional, joins as Vice President of Program Management BOSTON, Dec. 07, 2021 (GLOBE NEWSWIRE) — PepGen, Inc., …

PepGen Appoints Vice President of Program Management and Promotes Sonia Bracegirdle, Ph.D., to Senior Vice President, Strategy & Operations Read More »

PepGen Bolsters R&D Team with Appointment of Jaya Goyal, Ph.D., as Executive Vice President of Research and Preclinical Development

BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) — PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, today announced the addition of Jaya Goyal, Ph.D., as Executive Vice President of Research and Preclinical Development. Dr. Goyal is an experienced scientific leader with an extensive background in biotech R&D, including in rare diseases. Most recently, …

PepGen Bolsters R&D Team with Appointment of Jaya Goyal, Ph.D., as Executive Vice President of Research and Preclinical Development Read More »

PepGen Appoints Noel Donnelly as Chief Financial Officer

New appointment represents continued expansion of PepGen’s leadership team in Boston following successful $112.5 million Series B financing BOSTON, Oct. 28, 2021 (GLOBE NEWSWIRE) — PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, today announced that it has appointed Noel Donnelly as Chief Financial Officer. Mr. Donnelly is an experienced finance and …

PepGen Appoints Noel Donnelly as Chief Financial Officer Read More »

PepGen Welcomes Esteemed Neurologist Dr. John Day to Scientific Advisory Board

BOSTON, Oct. 13, 2021 (GLOBE NEWSWIRE) — PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, today announced the appointment of neuromuscular neurologist John W. Day, M.D., Ph.D., to its Scientific Advisory Board. Dr. Day is a Professor of Neurology, Pediatrics (Genetics) and Pathology and Director of the Division of Neuromuscular Medicine at Stanford …

PepGen Welcomes Esteemed Neurologist Dr. John Day to Scientific Advisory Board Read More »

PepGen To Present Research on Enhanced Delivery Treatments for Neuromuscular Disease at Two Scientific Conferences in September

Presentations will highlight data supporting PepGen’s approach to developing treatments for Duchenne muscular dystrophy and myotonic dystrophy type 1 BOSTON, Sept. 20, 2021 (GLOBE NEWSWIRE) — PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular diseases, today announced that Chief Executive Officer James McArthur, Ph.D., will present on Pepgen’s Enhanced Delivery Oligonucleotide (EDO) therapeutic platform at two …

PepGen To Present Research on Enhanced Delivery Treatments for Neuromuscular Disease at Two Scientific Conferences in September Read More »